Data from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) show that a supplemental application for RG002C0106 Injection, submitted by Suzhou Rigerna Therapeutics Co., Ltd. together with Beijing Rigerna Pharmaceutical Technology Co., Ltd., was accepted on 10 October 2026 under acceptance number CXHB2600420. The application is registered as a Class 1 chemical drug, the category reserved for innovative drugs not previously marketed in China or abroad.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE, National Medical Products Administration (NMPA), China |
| Action | Application accepted (docketed for review) |
| Acceptance No. | CXHB2600420 |
| Product | RG002C0106 Injection |
| Drug Type | Chemical drug |
| Application Type | Supplemental application |
| Registration Class | Class 1 (innovative drug) |
| Applicants | Suzhou Rigerna Therapeutics Co., Ltd. (Suzhou Xuanjing Biotechnology); Beijing Rigerna Pharmaceutical Technology Co., Ltd. |
| Acceptance Date | 10 Oct 2026 |
| Indication / Nature of Supplement | Not disclosed in the CDE docket |
Application Profile – What the Docket Shows
- Product Code: RG002C0106 Injection — an injectable formulation within the Rigerna “RG002” program family; the specific molecular entity, target, and mechanism were not disclosed in the CDE acceptance record.
- Drug Type: Chemical drug (化药) — the acceptance-number prefix CXHB corresponds to a domestic chemical-drug supplemental application, consistent with the docketed application type.
- Registration Class 1: China’s Class 1 designation applies to innovative drugs not marketed domestically or internationally, indicating the underlying program is a novel therapeutic entity rather than a generic or改良 follow-on. (Regulatory classification background.)
- Supplemental Application: A supplemental application (补充申请) typically covers post-approval or in-development changes — such as new indications, dosage forms, specifications, or manufacturing processes — to an existing registration; the specific subject of this supplement was not disclosed.
- Dual Applicants: The filing lists both the Suzhou parent R&D entity and its Beijing affiliate, reflecting a group-level regulatory strategy across the Rigerna organization.
Regulatory Pathway Context – CDE Acceptance Workflow
- Acceptance Meaning: CDE acceptance confirms the application package is complete and admissible, initiating formal technical review; acceptance is not an approval and confers no marketing rights.
- Review Sequence: Following acceptance, the application proceeds through technical evaluation, with potential supplementary-information requests, before a final approval decision; statutory review timelines apply per NMPA procedures.
- Class 1 Priority Tools: Innovative Class 1 programs may be eligible for expedited pathways (breakthrough therapy, priority review) where criteria are met; no such designation was indicated in this docket.
- Transparency: CDE dockets publish acceptance numbers, applicants, and application types, providing the public record on which this brief is based.
Market Impact & Outlook
- Pipeline Advancement: The acceptance moves the RG002C0106 program to a formal regulatory review stage in China, adding a near-term regulatory milestone to Rigerna’s portfolio.
- Innovative-Drug Positioning: Class 1 registration status positions the program within China’s incentive framework for first-in-market innovative therapeutics.
- Information Gap: With indication, mechanism, trial status, and the nature of the supplemental change undisclosed, the commercial significance of this filing cannot yet be assessed; further CDE docket updates or company disclosures will be required.
- Competitive Landscape: Not assessable from the docket; the therapeutic area and target remain undisclosed.
- Next Steps: CDE technical review of acceptance No. CXHB2600420; any company commentary on the supplement’s subject matter was not available at the time of this brief.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the CDE review of the supplemental application for RG002C0106 Injection. Acceptance does not guarantee approval. The indication, mechanism, and subject of the supplemental application have not been disclosed, and actual regulatory outcomes may differ due to risks including review findings, supplementary data requests, and competitive dynamics.-Fineline Info & Tech
